全文获取类型
收费全文 | 1028篇 |
免费 | 77篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 58篇 |
妇产科学 | 13篇 |
基础医学 | 90篇 |
口腔科学 | 29篇 |
临床医学 | 170篇 |
内科学 | 202篇 |
皮肤病学 | 12篇 |
神经病学 | 59篇 |
特种医学 | 277篇 |
外科学 | 58篇 |
综合类 | 22篇 |
预防医学 | 32篇 |
眼科学 | 9篇 |
药学 | 42篇 |
中国医学 | 5篇 |
肿瘤学 | 31篇 |
出版年
2023年 | 8篇 |
2022年 | 4篇 |
2021年 | 10篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 23篇 |
2017年 | 13篇 |
2016年 | 20篇 |
2015年 | 23篇 |
2014年 | 26篇 |
2013年 | 29篇 |
2012年 | 21篇 |
2011年 | 28篇 |
2010年 | 41篇 |
2009年 | 62篇 |
2008年 | 32篇 |
2007年 | 16篇 |
2006年 | 17篇 |
2005年 | 11篇 |
2004年 | 12篇 |
2003年 | 22篇 |
2002年 | 15篇 |
2001年 | 15篇 |
2000年 | 13篇 |
1999年 | 16篇 |
1998年 | 51篇 |
1997年 | 52篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 14篇 |
1991年 | 7篇 |
1990年 | 14篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 9篇 |
1982年 | 23篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1957年 | 2篇 |
1954年 | 2篇 |
排序方式: 共有1112条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Tobias Engelhorn Sophia Goerike Arnd Doerfler Christine Okorn Michael Forsting Gerd Heusch Rainer Schulz 《Journal of cerebral blood flow and metabolism》2004,24(4):467-474
The goal of the present study was to test the impact of administration time of the angiotensin II type 1-receptor blocker candesartan on cerebral blood flow (CBF), infarct size, and neuroscore in transient cerebral ischemia. Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion. Rats received 0.5-mg/kg candesartan intravenously 2 hours before MCAO (pretreatment), 24 hours after MCAO, every 24 hours after MCAO, or 2 hours before and every 24 hours after MCAO. Infarct size (mm3) and a neuroscore at day 7 were compared with controls. CBF was quantified by radiolabeled microspheres and laser-Doppler flowmetry. Compared with controls (95 +/- 8), infarct size in candesartan-treated groups was smaller (59 +/- 5, 68 +/- 10, 28 +/- 3, and 15 +/- 3, respectively; P<0.05). Although there was no difference in neuroscore between pretreatment and controls (1.55 +/- 0.18, 1.80 +/- 0.13), other treatment regimens resulted in improved neuroscores (1.33 +/- 0.16, 1.11 +/- 0.11, 0.73 +/- 0.15; P<0.05). CBF in pretreated animals at 0.5 hours after MCAO was significantly higher than in controls (0.58 +/- 0.09 mL x g(-1) x min(-1) and 44% +/- 7% of baseline compared with 0.49 +/- 0.06 mL x g(-1) x min(-1) and 37% +/- 6%, microspheres and laser-Doppler flowmetry; P<0.05). Thus, candesartan reduces infarct size even if administered only during reperfusion. Apart from pretreatment, other treatment regimens result in significantly improved neuroscores. In the acute phase of cerebral ischemia, candesartan increases CBF. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.